Skip to main content
. Author manuscript; available in PMC: 2023 Aug 16.
Published in final edited form as: Cell Metab. 2023 Apr 20;35(6):1009–1021.e9. doi: 10.1016/j.cmet.2023.03.021

Figure 3. AKT inhibition attenuate hepatomegaly, hepatosteatosis and hyperlipidemia but not hypoglycemia.

Figure 3.

(A) Gross liver morphology of 8-wo Fbp1F/F and Fbp1ΔHep mice treated −/+ MK2206 (100 mg/kg) or Torin1 (10 mg/kg), followed by 16 h fast before sacrifice.

(B-D) H&E (B) and ORO staining (C) of liver sections from 3A (n=4–5). Scale bars, 20 μm. ORO staining intensity per HMF was determined by Image J (D).

(E-I) Liver TG (E), serum TG (F), serum glucose (G), serum cholesterol (H) and liver/body weight ratio (I) in indicated mice (n=4–5).

Data are presented as mean ± SEM. n.s., not significant, P≥0.05. *P < 0.05, **P < 0.01, ***P < 0.001, ****p < 0.0001 (Unpaired two-tailed t test).